Literature DB >> 7543028

Taxol encapsulation in poly(epsilon-caprolactone) microspheres.

S K Dordunoo1, J K Jackson, L A Arsenault, A M Oktaba, W L Hunter, H M Burt.   

Abstract

Poly(epsilon-caprolactone) (PCL) microspheres containing taxol were prepared by the solvent evaporation method and tested for angiogenesis inhibition using the chick chorioallantoic membrane (CAM) model. Very high encapsulation efficiencies (95%) for taxol in PCL microspheres were obtained. In vitro release studies showed about 25% of the loaded drug was released in 6 weeks from microspheres containing 5% taxol. Studies with the CAM showed that taxol released from the microspheres induced vascular regression and inhibited angiogenesis.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7543028     DOI： 10.1007/bf00689043

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  12 in total

1.  Physico-mechanical properties of degradable polymers used in medical applications: a comparative study.

Authors:  I Engelberg; J Kohn
Journal:  Biomaterials       Date:  1991-04       Impact factor: 12.479

2.  Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution.

Authors:  S Kamei; H Okada; Y Inoue; T Yoshioka; Y Ogawa; H Toguchi
Journal:  J Pharmacol Exp Ther       Date:  1993-01       Impact factor: 4.030

3.  Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques.

Authors:  T Sato; M Kanke; H G Schroeder; P P DeLuca
Journal:  Pharm Res       Date:  1988-01       Impact factor: 4.200

4.  Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride.

Authors:  T Ichihara; K Sakamoto; K Mori; M Akagi
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

5.  Cytoskeletal agents inhibit motility and adherence of human tumor cells.

Authors:  M L Stracke; M Soroush; L A Liotta; E Schiffmann
Journal:  Kidney Int       Date:  1993-01       Impact factor: 10.612

6.  Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

Authors:  N M Lopes; E G Adams; T W Pitts; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  The preparation and evaluation of drug-containing poly(dl-lactide) microspheres formed by the solvent evaporation method.

Authors:  R Bodmeier; J W McGinity
Journal:  Pharm Res       Date:  1987-12       Impact factor: 4.200

8.  Ethylene-vinyl acetate copolymer microspheres for controlled release of macromolecules.

Authors:  M V Sefton; L R Brown; R S Langer
Journal:  J Pharm Sci       Date:  1984-12       Impact factor: 3.534

Review 9.  Taxol: a novel investigational antimicrotubule agent.

Authors:  E K Rowinsky; L A Cazenave; R C Donehower
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

10.  Arterial chemoembolization with cisplatin microcapsules.

Authors:  Y Okamoto; A Konno; K Togawa; T Kato; Y Tamakawa; Y Amano
Journal:  Br J Cancer       Date:  1986-03       Impact factor: 7.640
View more
  12 in total

1.  Effect of particle size of nanospheres and microspheres on the cellular-association and cytotoxicity of paclitaxel in 4T1 cells.

Authors:  Sinjan De; Donald W Miller; Dennis H Robinson
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

Review 2.  Progress in the development of alternative pharmaceutical formulations of taxanes.

Authors:  B Nuijen; M Bouma; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

3.  Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

Authors:  Naveed Shaik; Nagdeep Giri; William F Elmquist
Journal:  J Pharm Sci       Date:  2009-11       Impact factor: 3.534

Review 4.  Nanotechnology for angiogenesis: opportunities and challenges.

Authors:  Saeid Kargozar; Francesco Baino; Sepideh Hamzehlou; Michael R Hamblin; Masoud Mozafari
Journal:  Chem Soc Rev       Date:  2020-06-15       Impact factor: 54.564

5.  An assay to measure angiogenesis in human fat tissue.

Authors:  Frank L Greenway; Zhijun Liu; Ying Yu; Mary K Caruso; Andrew T Roberts; John Lyons; Joshua E Schwimer; Alok K Gupta; Drake E Bellanger; Thomas S Guillot; Eugene A Woltering
Journal:  Obes Surg       Date:  2007-04       Impact factor: 4.129

6.  Angiogenesis in head and neck cancer: a review of the literature.

Authors:  Codecà Carla; Ferrari Daris; Bertuzzi Cecilia; Broggio Francesca; Crepaldi Francesca; Foa Paolo
Journal:  J Oncol       Date:  2011-11-10       Impact factor: 4.375

Review 7.  The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis.

Authors:  Domenico Ribatti
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-08

8.  Resveratrol alleviates inflammatory injury and enhances the apoptosis of fibroblast‑like synoviocytes via mitochondrial dysfunction and ER stress in rats with adjuvant arthritis.

Authors:  Jinsen Lu; Yongshun Zheng; Jiazhao Yang; Junqiang Zhang; Wei Cao; Xiaoyu Chen; Shiyuan Fang
Journal:  Mol Med Rep       Date:  2019-05-22       Impact factor: 2.952

Review 9.  The pharmacological bases of the antiangiogenic activity of paclitaxel.

Authors:  Guido Bocci; Antonello Di Paolo; Romano Danesi
Journal:  Angiogenesis       Date:  2013-02-07       Impact factor: 9.596

10.  Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection.

Authors:  Jong-Suep Baek; Ju-Heon Kim; Jeong-Sook Park; Cheong-Weon Cho
Journal:  Int J Nanomedicine       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.